Finance

Lists
ROP:SWX
Roche Holding AG Genussscheine
CHF 360.10
+1.41%
(+5.00) 1D
Jul 27, 5:30:44 PM GMT+2  ·   CHF
All symbols
SymbolPriceChange% Change
Generating top insights for ROP...
Open
CHF 358.90
High
CHF 363.10
Low
CHF 356.50
Mkt. cap
291.94B
Avg. vol.
1.02M
Volume
846.21K
Dividend
2.72%
Quarterly dividend
CHF 2.45
Ex-dividend date
Mar 27, 2025
P/E ratio
23.50
52-wk high
CHF 363.10
52-wk low
CHF 291.00
EPS
CHF 15.33
Shares outstanding
702.56M
No. of employees
113K
Open
CHF 358.90
High
CHF 363.10
Low
CHF 356.50
Mkt. cap
291.94B
Avg. vol.
1.02M
Volume
846.21K
Dividend
2.72%
Quarterly dividend
CHF 2.45
Ex-dividend date
Mar 27, 2025
P/E ratio
23.50
52-wk high
CHF 363.10
52-wk low
CHF 291.00
EPS
CHF 15.33
Shares outstanding
702.56M
No. of employees
113K
News stories
From sources across the web
Profile
F. Hoffmann-La Roche AG, commonly known as Roche, is a Swiss multinational holding healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. The company headquarters are located in Basel. Roche is the fifth-largest pharmaceutical company in the world by revenue and the leading provider of cancer treatments globally. In 2023, the company’s seat in Forbes Global 2000 was 76. The company owns the American biotechnology company Genentech, which is a wholly owned independent subsidiary, and the Japanese biotechnology company Chugai Pharmaceuticals, as well as the United States–based companies Ventana and Foundation Medicine. Roche's revenues during fiscal year 2020, were 58.32 billion Swiss francs. Descendants of the founding Hoffmann and Oeri families own slightly over half of the bearer shares with voting rights, with Swiss pharma firm Novartis owning a further third of its shares until 2021. F. Hoffmann-La Roche is a full member of the European Federation of Pharmaceutical Industries and Associations. Wikipedia
About Roche Holding AG Genussscheine
CEOThomas Schinecker
Employees113K
FoundedOct 1, 1896
HeadquartersBasel, Basel City, Switzerland
SectorPharmaceutical industry
Websiteroche.com
Previous reportsAll values in CHF
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CHF
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
15.75B
15.75B
15.73B
15.73B
Cost of goods sold
4.21B
4.21B
3.93B
3.93B
Cost of revenue
4.21B
4.21B
3.93B
3.93B
Research and development expenses
3.15B
3.15B
2.99B
2.99B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.59B
3.59B
3.22B
3.22B
Operating expense
6.82B
6.82B
6.11B
6.11B
Total operating expenses
11.03B
11.03B
10.04B
10.04B
Operating income
4.72B
4.72B
5.69B
5.69B
Other non operating income
-10.00M
-10.00M
-15.00M
-15.00M
EBT including unusual items
3.69B
3.69B
4.49B
4.49B
EBT excluding unusual items
4.37B
4.37B
5.37B
5.37B
Income tax expense
709.00M
709.00M
824.00M
824.00M
Effective tax rate
19.20%
19.20%
18.37%
18.37%
Other operating expenses
77.50M
77.50M
-96.50M
-96.50M
Net income
2.74B
2.74B
3.44B
3.44B
Net profit margin
17.36%
17.36%
21.85%
21.85%
Earnings per share
-
-
-
-
Interest and investment income
45.00M
45.00M
43.50M
43.50M
Interest expense
-289.50M
-289.50M
-282.00M
-282.00M
Net interest expenses
-244.50M
-244.50M
-238.50M
-238.50M
Depreciation and amortization charges
-
-
-
-
EBITDA
5.50B
5.50B
6.48B
6.48B
Gain or loss from assets sale
-21.50M
-21.50M
-2.50M
-2.50M
AI content may include mistakes. Learn more

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more